|
Match
|
Document |
Document Title |
|
|
US20140363453 |
Methods for Increasing Efficacy of FOLR1 Cancer Therapy
Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided. |
|
|
US20120100160 |
Methods for Inducing Mixed Chimerism
Fusion protein-siRNA complexes that specifically target activated T cells, and methods of use thereof, are described. |
|
|
US20120003217 |
HERCEPTIN® ADUVANT THERAPY
The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®. |
|
|
US20140199297 |
TRITERPENE GLYCOSIDE AND TRITERPENE COMPOSITIONS AND METHODS OF USING SAME
In the present invention, different strategies are used to improve the bioavailability of triterpene glycosides and triterpenes including, for example, (a) a covalent approach involving... |
|
|
US20110020373 |
IGE DIRECTED DNA VACCINATION
This invention is directed to a novel approach for focusing and expressing DNA vaccinates in Antigen Presenting Cells (APCs) mediated through targeting IgE receptors (FcεRs) on APC and driving DNA... |
|
|
US20140079721 |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. |
|
|
US20150151003 |
MAYTANSINOID DERIVATIVES
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen... |
|
|
US20140178415 |
MAYTANSINOID DERIVATIVES
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen... |
|
|
US20140178414 |
MAYTANSINOID DERIVATIVES
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen... |
|
|
US20150157736 |
HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE
The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such... |
|
|
US20140141025 |
HYDRAZINYL-INDOLE COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE
The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of... |
|
|
US20140314794 |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the... |
|
|
US20150165067 |
COMPOUNDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) AND METHODS OF TREATMENT
The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use... |
|
|
US20150165064 |
ENZYMATIC CONJUGATION OF POLYPEPTIDES
The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies,... |
|
|
US20110256157 |
PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases,... |
|
|
US20140220046 |
Sialic Acid Derivatives For Protein Derivatisation And Conjugation
Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde... |
|
|
US20140193438 |
ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR
Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the... |
|
|
US20140193489 |
Dopamine Nanocapsules and Uses Thereof
The present invention provides a sonochemical irradiation-based method for the preparation of polydopamine (PDA) nanocapsules having reduced wall thickness and uniform size distribution, which may... |
|
|
US20150071950 |
C-MET TARGETING COMPOUND-BIOACTIVE MATERIAL CONJUGATE AND USE THEREOF
Disclosed is a conjugate in which a c-Met targeting compound and a bioactive material are chemically conjugated with each other, and methods of use thereof. |
|
|
US20120276119 |
CD37-Binding Molecules and Immunoconjugates Thereof
Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune... |
|
|
US20110250216 |
METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS
Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted... |
|
|
US20150044238 |
METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS
Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers,... |
|
|
US20140161877 |
PEDERIN AND PSYMBERIN AGENTS
Compounds that include a pederin, psymberin or pederin/psymberin chimera scaffold. The pederin scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be... |
|
|
US20150118316 |
Nanoparticles of Cerium Oxide Targeted to an Amyloid Beta Antigen of Alzheimer's Disease and Associated Methods
Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and... |
|
|
US20110123436 |
Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA
Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises... |
|
|
US20140178413 |
COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to... |
|
|
US20140314667 |
METHODS OF TREATING EPIDERMAL GROWTH FACTOR DELETION MUTANT VIII RELATED DISORDERS
The present invention relates to methods of treating treating epidermal growth factor deletion mutant vIII (EGFRvIII) related disorders, such as glioblastoma or anaplastic astrocyte tumors, using... |
|
|
US20150209445 |
BIFUNCTIONAL CYTOTOXIC AGENTS
Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions. |
|
|
US20100260786 |
METHODS OF TREATING DRUG-RESISTANT CANCERS
Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. |
|
|
US20140178412 |
COMPOUNDS AND METHODS FOR THE TREATMENT OF EGFR POSITIVE DISEASES
Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates... |
|
|
US20140178411 |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES
Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to... |
|
|
US20130183270 |
Orally Bioavailable Lipid-Based Constructs
The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that... |
|
|
US20150044168 |
Treatment of Multiple Sclerosis With Anti-CD19 Antibody
The present invention provides for the treatment of multiple sclerosis through the use of chimeric and humanized versions of anti-CD19 antibodies that may mediate ADCC, CDC, and/or apoptosis. |
|
|
US20140205544 |
Cancer Treatment Comprising Therapeutics That Bind To Phosphatidylserine
Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor... |
|
|
US20140227297 |
TARGETED THERANOSTICS
Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems... |
|
|
US20150246136 |
NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective... |
|
|
US20140127240 |
Novel Binder-Drug Conjugates (ADCs) and Use of Same
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective... |
|
|
US20120183472 |
IMMUNOTHERAPY OF B-CELL MALIGNANCIES USING ANTI-CD22 ANTIBODIES
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to... |
|
|
US20120301490 |
IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE
An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an... |
|
|
US20140370037 |
DLL3 MODULATORS AND METHODS OF USE
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. |
|
|
US20140363455 |
DLL3 MODULATORS AND METHODS OF USE
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. |
|
|
US20130028919 |
TARGETED PYRROLOBENZODIAZAPINE CONJUGATES
Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs. |
|
|
US20130323169 |
THIOL-ENE CLICK CHEMISTRY FOR DRUG CONJUGATES
The present invention relates to linker molecules that readily conjugate cellular recognition ligand at one end and drug payload at the other, and are useful in treating or preventing cancer, an... |
|
|
US20150110816 |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention... |
|
|
US20140212411 |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention... |
|
|
US20130108620 |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention... |
|
|
US20090028821 |
PRODRUGS OF CC-A1065 ANALOGS
The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the... |
|
|
US20140140993 |
COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically... |
|
|
US20110287036 |
NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND
The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting... |
|
|
US20150250896 |
HYDROPHILIC LINKERS AND THEIR USES FOR CONJUGATION OF DRUGS TO A CELL BINDING MOLECULES
Cell binding agent-drug conjugates comprising hydrophilic linkers, and methods of using such linkers and conjugates are provided. |